SynthesisAnnals of surgical oncology2026
Immediate Lymphatic Reconstruction (ILR) for the Prevention of Lymphedema: A Meta-analysis of Prospective Clinical Trials.
Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Timing of Surgical Axillary Staging and Impact on Technical Success of Immediate Lymphatic Reconstruction Following Axillary Lymph Node Dissection.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Timing of Immediate Lymphatic Reconstruction-Expanding Access without Compromising Technical Success.Annals of surgical oncology · 2026Article
- Breast cancer-related lymphedema of the upper limb: integrating early surveillance and functional surgery into a synergistic management paradigm.Frontiers in surgery · 2026Review
- Microsurgical treatment of breast cancer-related lymphedema under contrast-enhanced ultrasound guidance: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the growing use of immediate lymphatic reconstruction (ILR) for preventing lymphedema, prospective long-term data on its efficacy remain limited.
objectiveThis study aimed to analyze long-term, prospective outcomes of ILR, utilizing all available outcome measures.
methodsOutcome data included the pooled cumulative incidence of lymphedema (assessed by limb measurements), odds ratio (OR), and relative risk (RR) for lymphedema development in patients who underwent ILR versus those who did not. Only prospective clinical trials with a minimum of 12 months of follow-up were included.
resultsNine prospective studies (2011-2024) were included, totaling 791 patients, with 460 undergoing ILR and an average follow-up of 20.6 ± 4.8 months. On average, 1.9 ± 0.4 anastomoses were performed per patient. ILR was associated with a significantly lower incidence of lymphedema: 9% (95% confidence interval [CI] 1-16%) compared with 29% (95% CI 11-46%) in the non-ILR group. Patients who received ILR had 69% lower odds of developing lymphedema compared with those without ILR (OR 0.31, 95% CI 0.19-0.51). A 58% reduction in lymphedema risk was also observed among ILR recipients (RR 0.42, 95% CI 0.26-0.68).
conclusionThis meta-analysis summarizing prospective data with a minimum of 12-month follow-up represents the largest evaluation to date of ILR with extended follow-up for lymphedema prevention. The findings demonstrate that ILR significantly reduces the incidence, odds, and risk of lymphedema, supporting its role as an effective preventive strategy in at-risk patients.
Indexed as
Identifiers
40962960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.